With the third wave of biosimilars in the spotlight during the forecast period, revenues from the sensory organs market will dominate growth, finds Frost & Sullivan
SANTA CLARA, Calif., Dec. 10, 2020 /PRNewswire/ — Frost & Sullivan’s recent analysis, Access to New Therapy Areas to Drive Major Growth in the Global Biosimilars Market, 2020–2026, finds that the cost-benefit for end-users (patients) and ease of partnering with specialty contract development and manufacturing organizations (CDMOs) are driving the global biosimilars market. The third wave of biosimilars, with patent expiries from 2020 onward, is expected to hit the global market, covering complex biologic molecules like certain high-value mAbs and targeted therapies. The global biosimilars market is set to grow from $30.4 billion in 2020 to $79.2 billion by 2026 at a CAGR of 17.3%. The third-wave biosimilars market is estimated to register staggering growth during the same period, reaching $5.46 billion by 2026 at an astounding 139.4% compound annual growth rate (CAGR).
For further information on this analysis, please visit: http://frost.ly/4zt
“With the onset of the third-wave biosimilars, partnerships and collaborations with CDMOs and other biopharmaceutical companies with exclusive commercial rights to markets will be the preferred business model in the biosimilars market. This will give companies improved access to new markets and enable higher market penetration,” said Deepak Jayakumar, Healthcare Industry Analyst at Frost & Sullivan. “The patent expiry of blockbuster biologics such as adalimumab, aflibercept, and ustekinumab in 2023 will result in the highest year-wise market revenue contribution from patent expiry.”
Jayakumar added: “From a drug-type perspective, while a large number of recombinant protein biologics are set for patent expiry between 2020 and 2026, the antibody therapy segment will have a higher cumulative market revenue as a higher number of blockbusters in the segment are set to lose their patent over the forecast period. Similarly, from the therapy area viewpoint, musculoskeletal, oncology, and immunomodulators will continue to generate high market revenues as they will be primarily driven by biosimilars. Sensory organs will be the highest revenue-generating segment among the newer therapy areas set to enter the market with the third wave of biosimilars.”
To benefit from the growth prospects exposed by the third wave of biosimilars, market participants need to focus on the following:
- Provide real-world evidence (RWE) to substantiate the interchangeability claim.
- Collaborate with others and leverage novel discovery platforms.
- Expand the market base in different geographies, such as India, and understand domestic market dynamics.
- Accelerate the development of aflibercept and ranibizumab biosimilars and pre-register them before the biologics’ patent expiry to gain a first-to-market advantage.
Access to New Therapy Areas to Drive Major Growth in the Global Biosimilars Market, 2020–2026 is the latest addition to Frost & Sullivan’s Healthcare research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Access to New Therapy Areas to Drive Major Growth in the Global Biosimilars Market, 2020–2026
The content is by PR NewsWire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.